|
| Press Releases |
|
 |
|
| Monday, May 8, 2023 |
|
|
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration |
| Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration. more info >> |
|
|
エーザイ、抗体薬物複合体BB-1701について、BlissBioと戦略的提携に向けたオプション権を有する共同開発契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗体薬物複合体（Antibody-Drug Conjugate：ADC）である BB-1701 について、Bliss Biopharmaceutical(Hangzhou) Co., Ltd.（本社：中国浙江省、以下 BlissBio）と戦略的提携に向けたオプション権を有する共同開発契約を締結したことをお知らせします。 more info >> |
|
| Thursday, April 6, 2023 |
|
|
Eisai Completes a Major Renovation of Tsukuba Research Laboratories |
| Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond". more info >> |
|
|
エーザイ、筑波研究所の大規模改修工事が竣工 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社の中期経営計画 EWAY Future & Beyond における戦略投資の一環として実施した筑波研究所（茨城県）の大規模改修工事が竣工したことをお知らせします。 more info >> |
|
| Tuesday, April 4, 2023 |
|
|
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy. more info >> |
|
|
エーザイ、臨床第III相Clarity AD試験データを用いた「レカネマブ」の長期的健康アウトカムについて、シミュレーションを用いた評価結果が査読学術専門誌Neurology and Therapy誌に掲載 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、アルツハイマー病（AD）による軽度認知障害（MCI）および軽度AD（総称して早期ADと定義）当事者様に対する抗アミロイドβ（Aβ）プロトフィブリル*抗体レカネマブ（一般名、米国ブランド名「LEQEMBITM」）の長期的な健康アウトカムへの影響をシミュレーション評価した結果が、査読学術専門誌Neurology and Therapy別ウィンドウで開きます誌に掲載されたことをお知らせします。 more info >> |
|
| Monday, April 3, 2023 |
|
|
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System |
| Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system. more info >> |
|
|
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、EZH2 阻害剤タゼメトスタット臭化水素酸塩（一般名、製品名：「タズベリク(R)錠 200mg」、以下 タゼメトスタット）について、国立研究開発法人国立がん研究センターと、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を締結したことをお知らせします。本臨床研究は、国立がん研究センター中央病院によって実施されます。 more info >> |
|
| Friday, March 31, 2023 |
|
|
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL). more info >> |
|
|
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals |
| Eisai Co., Ltd. and Biogen Inc. announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱造船、アンモニアを燃料とする大型アンモニア輸送船の設計基本承認（AiP）を船級協会から取得
Mar 14, 2025 14:15: JST
|
|
|
富士通、「第57回（令和６年度）市村賞 市村産業賞」の「貢献賞」を受賞
Mar 14, 2025 12:50: JST
|
|
|
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
Mar 14, 2025 10:18: JST
|
|
|
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
Mar 14, 2025 09:18 HKT/SGT
|
|
|
TreasureNFT Introduces New Features to Enhance NFT Trading Efficiency
Mar 14, 2025 09:00: JST
|
|
|
TreasureNFT Introduces New Features to Enhance NFT Trading Efficiency
Mar 14, 2025 08:00 HKT/SGT
|
|
|
CleverTap partners with upGrad to build a Deep Learning Track to upskill Marketers with Hands-On AI & Analytics Training
Mar 14, 2025 04:00 HKT/SGT
|
|
|
Hong Kong delegation concludes IRES mission in Bangkok
Mar 13, 2025 16:41: JST
|
|
|
Lit Studios enters into MOU with Bingo Group, a Hong Kong listed company
Mar 13, 2025 16:19 HKT/SGT
|
|
|
CleverTap partners with upGrad to build a Deep Learning Track to upskill Marketers with Hands-On AI & Analytics Training
Mar 13, 2025 16:00: JST
|
|
|
Hong Kong delegation concludes IRES mission in Bangkok
Mar 13, 2025 15:41 HKT/SGT
|
|
|
SRKay Consulting Group Unveils Research on Why New-Shoring is Replacing Traditional Offshoring
Mar 13, 2025 15:05 HKT/SGT
|
|
|
Honda、第4回日経統合報告書アワード優秀賞を初受賞
Mar 13, 2025 14:15: JST
|
|
|
TOYOTA、新型クラウン（エステート）を発売
Mar 13, 2025 14:10: JST
|
|
|
Hokkaido Electric Power Corporation and Mitsubishi Corporation Establish a Joint Venture "Hokkaido Renewable Energy Aggregation Co., Ltd."
Mar 13, 2025 13:26 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
